INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH



Unlocking The Potential of Extracellular Vesicles for Therapeutic and Diagnostic Application

Sanjay Kumar Yadav*, Ajit Kiran Kaur
Accurate College of Pharmacy Greater Noida

Keywords:
Extracellular vesicles, EVs, drug delivery, regenerative medicine, immunomodulation, cancer therapy, biomarkers, imaging techniques, intercellular communication.

Corresponding Author-
Sanjay Kumar Yadav
Email:
sy30061981@gmail.com
Accurate College of Pharmacy Greater Noida

Volume 15, Issue 2, 2024
Received: 7 April 2024
Accepted: 15 April 2024
Published: 30 April 2024
DOI:
10.69580/IJPPR.15.2.2024.32-51

ABSTRACT: Extracellular Vesicles (EVs) have emerged as promising candidates for both therapeutic interventions and diagnostic applications due to their unique biological properties and ability to facilitate intercellular communication. This review explores the diverse potential of EVs in the fields of therapeutics and diagnostics. We discuss the biogenesis and composition of EVs, highlighting their cargo of proteins, nucleic acids, and lipids. Furthermore, we delve into the therapeutic applications of EVs, including drug delivery, regenerative medicine, immunomodulation, and cancer therapy. Additionally, we examine the diagnostic utility of EVs, focusing on their role in biomarker discovery and imaging techniques for visualization. Challenges and future directions in EV research, including standardization, clinical translation, and emerging technologies, are also discussed. Overall, this review provides insights into the current understanding of EVs and their potential to revolutionize therapeutic and diagnostic approaches in various disease contexts.

1. Introduction

Extracellular Vesicles (EVs) are small membrane-bound vesicles released by cells into the extracellular environment. They are important mediators of intercellular communication, facilitating the transfer of bioactive molecules such as proteins, nucleic acids, and lipids between cells. EVs play diverse roles in physiological processes including immune regulation, tissue homeostasis, and cellular signaling.[1] These vesicles are highly heterogeneous in terms of size, composition, and biogenesis, encompassing subtypes such as exosomes, microvesicles, and apoptotic bodies. Understanding the biology and functions of EVs has garnered significant interest due to their potential implications in various disease contexts, including cancer, neurodegenerative disorders, and cardiovascular diseases. This review aims to explore EVs' therapeutic and diagnostic potential, elucidating their role in

revolutionizing medical approaches toward addressing complex health challenges.[2,3]

2. Importance of EVs in intercellular communication

Extracellular Vesicles (EVs) are essential mediators of intercellular communication, facilitating the transfer of bioactive molecules between cells and influencing various physiological and pathological processes.[4] These small membrane-bound vesicles carry proteins, nucleic acids, lipids, and other biomolecules, allowing for direct communication between neighboring or distant cells. Their role in maintaining tissue homeostasis and coordinating physiological processes is paramount, with EVs derived from stem cells being particularly noteworthy for their ability to promote tissue repair and regeneration by delivering growth factors and other regenerative molecules to injured cells or tissues.[5]

Moreover, EVs play crucial roles in immune regulation, modulating immune responses through the transfer of immunomodulatory molecules such as cytokines and surface receptors. In cancer progression and metastasis, EVs derived from cancer cells contribute significantly by promoting angiogenesis, immune evasion, and the preparation of pre-metastatic niches in distant organs.[6] They also facilitate the transfer of oncogenic molecules and genetic material, thus altering the behavior of recipient cells to support tumor growth.[7,8] In the nervous system, EVs participate in synaptic communication, neuronal development, and maintenance of neuronal health by transporting neurotransmitters, synaptic proteins, and signaling molecules.[9] Additionally, EVs hold promise as diagnostic biomarkers for various diseases, given their diverse cargo reflective of the cell of origin and pathological state. Analysis of EV cargo, such as miRNAs or proteins, in biofluids like blood or cerebrospinal fluid, provides valuable insights into disease progression and prognosis. In conclusion, understanding the mechanisms underlying EV-mediated communication is crucial for harnessing their full potential in therapeutic interventions and diagnostic applications across various health conditions.[10,11] The various importance of EVs in intercellular communication are mentioned in Figure 1.



Figure 1: Importance of EVs in intercellular communication

3. Therapeutic and Diagnostic Potential

Extracellular Vesicles (EVs) offer a vast potential in both therapeutic interventions and diagnostic applications due to their unique properties and ability to convey molecular information between cells. From a therapeutic standpoint, EVs hold promise as vehicles for drug delivery, with the potential to transport various therapeutic payloads, including drugs, proteins, and nucleic acids, to specific target cells or tissues. This targeted delivery system could enhance therapeutic efficacy while minimizing off-target effects.[12,13] Moreover, EVs derived from regenerative cell types, such as stem cells, exhibit regenerative properties and can stimulate tissue repair and regeneration, making them promising candidates for regenerative medicine applications. Additionally, EVs possess immunomodulatory capabilities, allowing them

to influence immune responses and potentially be used in immune-related disorders or as adjuvants in cancer immunotherapy. In the context of cancer therapy, EVs have shown potential in modulating tumor microenvironments, suppressing tumor growth, and enhancing immune responses against cancer cells.[14,15]

On the diagnostic front, EVs offer a non-invasive means of disease detection and monitoring. The molecular cargo carried by EVs, including proteins, nucleic acids, and lipids, reflects the physiological or pathological state of their parent cells. This characteristic makes EVs valuable as diagnostic biomarkers for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. By analyzing the composition of EV cargo in biofluids such as blood, urine, or cerebrospinal fluid, clinicians can gain insights into disease progression, prognosis, and treatment response. Furthermore, advances in imaging techniques enable the visualization and tracking of EVs in vivo, providing opportunities for real-time monitoring of disease processes and therapeutic interventions.16,17

In summary, the therapeutic and diagnostic potential of EVs is vast and multifaceted. Their ability to modulate cellular processes, deliver therapeutic payloads, and serve as diagnostic biomarkers holds great promise for revolutionizing medical approaches to various diseases. However, challenges such as standardization, scalability, and clinical translation need to be addressed to fully realize the potential of EV-based therapies and diagnostics.[18–20]

4. Types of Extracellular Vesicles

Extracellular Vesicles (EVs) encompass various types, each with distinct biogenesis mechanisms, sizes, and functions. The three main types of EVs are exosomes, microvesicles (also known as ectosomes or shedding vesicles), and apoptotic bodies.[21,22]

4.1 Exosomes

Exosomes are a subtype of extracellular vesicles (EVs) that play crucial roles in intercellular communication. They are formed through the endosomal pathway within cells. Initially, early endosomes mature into late endosomes, also known as multivesicular bodies (MVBs), through inward budding of the endosomal membrane. Subsequently, MVBs fuse with the cell's plasma membrane, releasing exosomes into the extracellular space. Exosomes typically range in size from 30 to 150 nanometers in diameter.[23–25]

Exosomes carry a diverse cargo of bioactive molecules, including proteins, lipids, and nucleic acids such as microRNAs (miRNAs) and mRNAs. These molecules reflect the physiological or pathological state of the cell of origin. Exosomes play essential roles in various physiological processes, including immune regulation, tissue homeostasis, and neuronal communication.[26,27]

In the context of disease, exosomes derived from cancer cells contribute to tumor progression and metastasis by facilitating communication within the tumor microenvironment and influencing recipient cells in distant organs. Conversely, exosomes derived from stem cells exhibit regenerative properties and can promote tissue repair and regeneration.[28]

4.1.1 Biogenesis

4.1.1.1 Exosome Biogenesis (Endosomal Pathway)

Exosomes originate from the endosomal pathway and are formed within multivesicular bodies (MVBs). The biogenesis of exosomes involves several steps

- **Early Endosome Formation**: The process begins with the inward budding of the plasma

membrane, leading to the formation of early endosomes that engulf extracellular materials.[29]

- **Maturation into Late Endosomes (MVBs)**: As early endosomes mature, they accumulate intraluminal vesicles (ILVs) within their lumen, forming MVBs. This process involves the inward budding of the endosomal membrane, leading to the sequestration of cytoplasmic contents into ILVs.[30–32]

- **Cargo Sorting**: Various mechanisms, including the endosomal sorting complexes required for transport (ESCRT) machinery, tetraspanins, and lipid microdomains, are involved in sorting specific cargo into ILVs. ESCRT complexes help recruit ubiquitinated proteins to the endosomal membrane for incorporation into ILVs.[33]

- **Exosome Release**: MVBs can either fuse with lysosomes for degradation or traffic to the plasma membrane for exocytosis. Upon fusion with the plasma membrane, MVBs release their ILVs as exosomes into the extracellular space.[34]

4.2 Microvesicles

Microvesicles, also known as ectosomes or shedding vesicles, represent another type of extracellular vesicle (EV) that plays a significant role in intercellular communication and various physiological processes. Unlike exosomes, which are generated through the endosomal pathway, microvesicles are formed by direct budding and shedding of the plasma membrane in response to cellular activation, stress, or apoptosis.[35,36]

These vesicles range in size from approximately 100 to 1000 nanometers in diameter, making them larger than exosomes but smaller than apoptotic bodies. Their size and biogenesis contribute to their ability to carry a diverse cargo of cellular components, including proteins, lipids, and membrane receptors. Microvesicles function as vehicles for the transfer of bioactive molecules between cells, thereby mediating intercellular communication and influencing cellular behavior.[37]

Microvesicles have been implicated in various physiological processes, including immune responses, inflammation, coagulation, and tissue repair. In pathological conditions such as cancer, microvesicles derived from tumor cells play roles in promoting tumor progression, metastasis, and immune evasion. Additionally, microvesicles released by activated immune cells contribute to inflammatory responses and modulate immune cell functions.[38,39]

The cargo carried by microvesicles, including signaling molecules, growth factors, and genetic material, reflects the physiological or pathological state of the parent cell. Therefore, analysis of microvesicle cargo has diagnostic potential, offering insights into disease progression, prognosis, and treatment response. Overall, microvesicles represent an important class of extracellular vesicles with diverse functions and potential implications in health and disease. Further research into their biogenesis, cargo, and functional roles is essential for unlocking their full therapeutic and diagnostic potential.[40,41]

Microvesicles, also known as ectosomes or shedding vesicles, are generated directly from the plasma membrane through outward budding and fission. The process involves cytoskeletal rearrangements and lipid redistribution, leading to the formation and release of microvesicles into the extracellular environment. Microvesicle shedding can be triggered by various stimuli, including cell activation, stress, and injury.[42]

4.3 Apoptotic bodies

Apoptotic bodies are a type of extracellular vesicle (EV) generated during programmed cell death, known as apoptosis. As cells undergo

apoptosis, they undergo characteristic morphological changes, including chromatin condensation, nuclear fragmentation, and membrane blebbing, leading to the formation of apoptotic bodies.[43]

Apoptotic bodies are relatively larger than other types of EVs, ranging from 500 to 5000 nanometers in diameter. They contain a variety of cellular contents, including organelles, fragmented DNA, and cytoplasmic components, encapsulated within their membrane-bound structure.[44]

The formation of apoptotic bodies serves as a mechanism for the controlled disposal of dying cells and prevents the release of potentially harmful cellular contents into the surrounding tissue. Following their formation, apoptotic bodies are recognized and engulfed by phagocytic cells, such as macrophages, through a process called efferocytosis.[45]

In addition to their role in the clearance of apoptotic cells, apoptotic bodies also play roles in immune modulation. They may contain immunogenic molecules, including antigens and danger-associated molecular patterns (DAMPs), which can influence immune responses and promote the resolution of inflammation.[46]

Furthermore, apoptotic bodies have been implicated in cell-to-cell communication, as they can transfer cellular components and signaling molecules to neighboring or distant cells. This intercellular communication mediated by apoptotic bodies may have implications in various physiological processes and pathological conditions, including tissue homeostasis, immune regulation, and cancer progression.[47,48]

Overall, apoptotic bodies represent an important aspect of cellular biology, serving both as mediators of cell clearance and as contributors to intercellular communication and immune regulation. Further research into the formation, composition, and functional roles of apoptotic bodies is essential for understanding their significance in health and disease.[49]

5 Composition of EV cargo (proteins, nucleic acids, lipids)

Extracellular vesicles (EVs) carry a diverse cargo of biomolecules, including proteins, nucleic acids, lipids, and various other molecules mentioned in figure 2. The composition of EV cargo:

5.1 Proteins

EVs contain a wide array of proteins derived from their parental cells. These proteins can include:

- **Membrane proteins:** Proteins embedded within the lipid bilayer of EV membranes, such as tetraspanins (CD9, CD63, CD81), integrins, and various receptors.[50]
- **Cytosolic proteins:** Proteins that are present within the cytoplasm of the parental cell and are encapsulated within the EVs during their biogenesis. These may include enzymes, cytoskeletal proteins, heat shock proteins (HSPs), and signaling molecules.[51,52]
- **Surface-associated proteins:** Proteins that associate with the surface of EVs but may not necessarily be integral membrane proteins, such as adhesion molecules and immunomodulatory proteins.[53–55]

5.2 Nucleic Acids

EVs contain various types of nucleic acids, including:

- **mRNA:** Messenger RNA molecules that can be transferred from donor cells to recipient cells via EVs, potentially leading to changes in gene expression.[56]
- **microRNA (miRNA):** Small non-coding RNA molecules that regulate gene expression by targeting specific mRNAs for degradation or translational repression.[57]

- **Other small non-coding RNAs:** EVs can also contain other types of small non-coding RNAs, such as small interfering RNA (siRNA), piwi-interacting RNA (piRNA), and small nucleolar RNA (snoRNA).[58]
- **DNA:** While less common than RNA, EVs may also contain DNA fragments, including genomic DNA, mitochondrial DNA, and viral DNA.[59]

5.3 Lipids

EV membranes are enriched in various lipid species, including:

- **Phospholipids:** Phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol are among the phospholipids found in EV membranes.[60]
- **Cholesterol:** EV membranes contain cholesterol, which plays a crucial role in membrane fluidity and stability.[61]
- **Sphingolipids:** Ceramide, sphingomyelin, and glycosphingolipids are examples of sphingolipids present in EV membranes.
- **Other lipid species:** EV membranes may also contain glycerophospholipids, lysophospholipids, and various lipid-modified proteins.[50,61]

5.4 Other Molecules

Additionally, EVs can carry various other molecules, including metabolites, carbohydrates, and signaling molecules, depending on the specific cargo sorting mechanisms and the physiological state of the parental cells.



Figure 2: Composition of EV cargo

6 Therapeutic Applications

Extracellular vesicles (EVs) have gained attention as promising vehicles for drug delivery due to their natural ability to transport various biomolecules and their inherent biocompatibility. Here's an overview of the therapeutic applications of EVs in drug delivery, including payload loading methods and targeted delivery

6.1 Drug Delivery

EVs offer several advantages for drug delivery:

- **Biocompatibility**: EVs are derived from cells and are naturally biocompatible, reducing the risk of immune reactions and toxicity.
- **Cellular Uptake**: EVs can efficiently deliver cargo molecules into target cells through various mechanisms, including endocytosis, membrane fusion, and receptor-mediated uptake.[62]
- **Stability**: EVs protect cargo molecules from degradation by enzymes and harsh extracellular conditions, enhancing their stability and bioavailability.
- **Minimal Immunogenicity**: EVs derived from autologous cells have low immunogenicity, reducing the likelihood of immune rejection.[63]

6.2 Payload Loading Methods

Various methods can be employed to load therapeutic payloads into EVs efficiently:

- **Incubation**: EVs can be loaded with hydrophobic drugs by incubating them with the drug in solution, allowing passive diffusion into the EV membrane.
- **Electroporation**: Electric pulses can be used to create transient pores in the EV membrane, facilitating the entry of cargo molecules into the vesicles.[64]
- **Sonication**: Ultrasonic waves can disrupt the EV membrane temporarily, enabling the loading of cargo molecules into the vesicles.
- **Genetic Engineering**: Parental cells can be genetically modified to overexpress specific proteins or nucleic acids, which are then incorporated into EVs during their biogenesis.[65]

6.3 Targeted Delivery to Specific Cells/Tissues

EVs can be engineered to achieve targeted delivery to specific cells or tissues

- **Surface Modification**: EVs can be surface-functionalized with targeting ligands, such as antibodies, peptides, or aptamers, that recognize receptors or antigens expressed on target cells.
- **Exosome Mimetics**: Synthetic nanoparticles, such as liposomes or polymersomes, can be engineered to mimic the properties of natural EVs and achieve targeted delivery by functionalizing their surface with targeting moieties.
- **Tissue Homing**: EVs derived from specific cell types, such as stem cells or immune cells, exhibit inherent tropism towards certain tissues or pathological microenvironments, enabling targeted delivery to diseased sites.[66]

6.4 Immunomodulation

EVs are involved in various aspects of immunomodulation, including:

- **Regulation of Immune Cell Activation:** EVs derived from immune cells, such as dendritic cells, macrophages, and T cells, can modulate the activation and function of other immune cells, such as T cells, B cells, natural killer (NK) cells, and antigen-presenting cells (APCs).[67]
- **Induction of Tolerance or Immune Suppression**: EVs can promote immune tolerance or suppress immune responses by delivering immunomodulatory molecules, such as cytokines, chemokines, and regulatory RNAs, to target cells.[68]
- **Modulation of Inflammatory Responses:** EVs can regulate inflammatory responses by promoting the secretion of anti-inflammatory cytokines or inhibiting the production of pro-inflammatory cytokines and chemokines.
- **Antigen Presentation and T Cell Activation:** EVs can carry antigens and major histocompatibility complex (MHC) molecules, facilitating antigen presentation to T cells and the activation of specific immune responses.[69]
- **Communication between Immune Cells and Non-immune Cells:** EVs mediate intercellular communication between immune cells and non-immune cells, such as endothelial cells, epithelial cells, and stromal cells, influencing tissue homeostasis and immune surveillance.[70]

6.5 Cancer Therapy

Extracellular vesicles (EVs) offer a promising avenue for cancer therapy. They serve as natural nanocarriers for delivering anti-cancer drugs, stimulate anti-tumor immune responses, enable targeted delivery to cancer cells, and provide

diagnostic biomarkers for cancer detection and monitoring. EV-based approaches hold significant potential for improving cancer treatment outcomes.[71]

6.5.1 Use of EVs in Cancer Immunotherapy

EV-based immunotherapies represent a promising strategy for leveraging the immune system to combat cancer. These therapies encompass various approaches aimed at enhancing anti-tumor immune responses and generating long-lasting immunity against cancer cells. One avenue involves the development of cancer vaccines using EVs derived from tumor cells or antigen-presenting cells (APCs), such as dendritic cells, which carry tumor antigens and adjuvants. These EV-based vaccines stimulate antigen-specific immune responses, leading to the generation of anti-tumor immunity. [68,72]

Additionally, EVs engineered to express immune checkpoint inhibitors, such as programmed cell death ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), can block immune checkpoint pathways, enhancing anti-tumor immune responses. Furthermore, EVs play a crucial role in tumor antigen presentation, delivering tumor antigens to APCs like dendritic cells, facilitating antigen presentation to T cells, and activating specific anti-tumor immune responses. Moreover, EV-based vaccines or immunotherapies have the potential to induce durable immune memory against tumor antigens, providing long-term protection against cancer recurrence. Overall, EV-based immunotherapies offer a multifaceted approach to cancer treatment, harnessing the immune system's capabilities to target and eliminate cancer cells effectively.[73]

6.5.2 Targeting Tumor Cells and Microenvironment

Extracellular vesicles (EVs) play crucial roles in both targeting tumor cells directly and influencing the tumor microenvironment, thereby impacting cancer progression, metastasis, and responses to therapy. Tumor cells release EVs that facilitate communication within the tumor microenvironment by transferring oncogenic proteins, nucleic acids, and signaling molecules to neighboring or distant cells, promoting tumor growth, invasion, and metastasis.74 Additionally, EVs derived from various cellular sources within the tumor microenvironment, including tumor cells, immune cells, and stromal cells, contribute to tumor-microenvironment crosstalk. These EVs modulate the tumor microenvironment by promoting processes such as angiogenesis, immune evasion, and tumor immune escape, thereby facilitating cancer progression and resistance to therapy. Furthermore, EVs engineered to carry anti-cancer agents, such as chemotherapeutic drugs, small interfering RNAs (siRNAs), or monoclonal antibodies, offer a promising approach for therapeutic targeting. These engineered EVs can be designed to target tumor cells directly or specific components of the tumor microenvironment, enhancing therapeutic efficacy while minimizing off-target effects. In summary, EVs play multifaceted roles in cancer biology, influencing both tumor cells and the tumor microenvironment, and hold significant potential as therapeutic targets and delivery vehicles in cancer treatment strategies.[75]

7. Diagnostic Applications

Diagnostic applications of extracellular vesicles (EVs) hold immense promise across various fields of medicine. EVs, including exosomes, microvesicles, and apoptotic bodies, serve as valuable sources of biomarkers for disease diagnosis, prognosis, and monitoring. Here are some key diagnostic applications of EVs

7.1 Biomarker Discovery

Extracellular vesicles (EVs) emerge as promising reservoirs for biomarker discovery due to their rich and diverse cargo originating from their parental cells. Through proteomic

analysis, EVs offer a window into the disease-specific protein signatures present within their contents. This allows for the identification of proteins that are indicative of particular diseases or conditions, thereby facilitating the discovery of novel biomarkers crucial for diagnosis, prognosis, and monitoring treatment responses. Furthermore, EVs harbor various nucleic acids, encompassing DNA, mRNA, microRNA (miRNA), and other non-coding RNAs, which serve as reflective indicators of genetic alterations and expression patterns associated with diseases. Leveraging EVs for nucleic acid profiling enables the identification of RNA-based biomarkers that can shed light on disease mechanisms and progression. Additionally, EV lipidomics and metabolomics analyses unravel alterations in lipid and metabolite profiles linked to diseases, offering valuable insights into disease pathogenesis and progression. The comprehensive molecular information carried by EVs underscores their potential as valuable sources for biomarker discovery, promising advancements in disease diagnosis, monitoring, and therapeutic interventions.[76]

EV cargo, including proteins, nucleic acids, lipids, and metabolites, can serve as biomarkers for disease diagnosis across various medical specialties. In cancer diagnosis, EVs shed by tumor cells carry tumor-specific biomarkers, such as mutated oncogenes, tumor-associated proteins, and nucleic acids, which can be detected in biofluids for cancer diagnosis and monitoring. For neurological disorders, EVs derived from neurons or glial cells carry disease-specific proteins or nucleic acids associated with conditions like Alzheimer's disease and Parkinson's disease, offering potential biomarkers for early detection and monitoring. Similarly, EVs released by damaged or stressed cells in the cardiovascular system carry biomarkers indicative of myocardial infarction, heart failure, and other cardiovascular diseases. Liquid biopsy applications harness the presence of EVs in biofluids such as blood, urine, saliva, and cerebrospinal fluid, offering minimally invasive sources for diagnostic testing. EV-based liquid biopsies enable the detection of tumor-derived EVs carrying cancer-specific biomarkers, facilitating early cancer detection, monitoring disease progression, and assessing treatment responses. Additionally, EVs released in response to infections can carry biomarkers indicative of infectious diseases, aiding in the diagnosis and management of various infectious conditions.[77]

7.2 Imaging Techniques for EV Visualization

Various imaging techniques are employed for the visualization and characterization of extracellular vesicles (EVs), offering insights into their morphology, size distribution, and composition. Electron microscopy stands as a cornerstone technique, providing high-resolution images that elucidate the ultrastructure of EVs. With electron microscopy, researchers can observe the morphology and membrane characteristics of EVs, distinguishing between different subtypes such as exosomes and microvesicles. Flow cytometry, on the other hand, enables the quantitative analysis of EVs based on their size and surface markers. By employing fluorescently labeled antibodies or nanoparticles, flow cytometry allows for the identification and enumeration of EV populations in complex samples. Nanoparticle tracking analysis complements these techniques by providing quantitative data on EV size distribution and concentration. By tracking the Brownian motion of individual EVs in suspension, nanoparticle tracking analysis offers valuable information on EV size and concentration, aiding in the characterization of EV populations. Collectively, these imaging techniques play pivotal roles in advancing our understanding of EV biology and facilitating their applications in diagnostics and therapeutics.[74,78]

8. Challenges and Future Directions

The field of extracellular vesicle (EV) research is rapidly advancing, yet it faces several challenges and opportunities for future development. One critical challenge is the standardization of EV isolation and characterization methods. Currently, there is a lack of consensus on standardized protocols for EV isolation, leading to variability in EV preparations across studies. Addressing this challenge requires collaborative efforts to establish standardized protocols for EV isolation and characterization, ensuring reproducibility and comparability of results across different research groups.[79]

Another significant challenge is addressing concerns regarding EV heterogeneity. EVs exhibit heterogeneity in terms of size, composition, and biogenesis pathways, which can impact their functional properties and biological activities. Understanding and characterizing this heterogeneity are essential for elucidating the roles of EVs in health and disease. Future research should focus on developing methods to classify and characterize EV subpopulations based on their specific properties and functional relevance.[80]

Furthermore, the clinical translation of EV-based therapeutics and diagnostics requires careful consideration of regulatory considerations and validation requirements. Regulatory agencies have yet to establish clear guidelines for the clinical use of EVs, including quality control standards, safety assessments, and efficacy evaluations. Overcoming these regulatory hurdles will require collaboration between researchers, clinicians, industry stakeholders, and regulatory agencies to develop standardized protocols and guidelines for the clinical translation of EV-based products.[81]

Despite these challenges, the field of EV research is witnessing significant advancements driven by emerging technologies and innovations. Novel techniques for EV isolation, such as microfluidics-based approaches, immunoaffinity capture, and size-based filtration systems, offer improved efficiency, purity, and scalability compared to conventional methods. Moreover, cutting-edge technologies, including single-vesicle analysis, advanced imaging modalities, and high-throughput omics profiling, enable comprehensive characterization of EVs at the single-particle level, providing unprecedented insights into their biology and functions.[82]

9. Conclusion

Extracellular vesicles (EVs) represent a promising frontier in both therapeutics and diagnostics, offering a wealth of potential for revolutionizing medical practice. EVs have emerged as versatile vehicles for targeted drug delivery, with the ability to transport a diverse cargo of biomolecules, including proteins, nucleic acids, and lipids, to specific cells or tissues. This capability holds immense promise for the development of precise and effective treatments for a wide range of diseases, including cancer, neurological disorders, cardiovascular diseases, and autoimmune conditions. Additionally, EVs serve as rich sources of biomarkers for disease diagnosis, prognosis, and treatment response monitoring, offering non-invasive approaches such as liquid biopsy for early detection and monitoring of diseases.

Looking ahead, the future outlook for EV-based therapies and diagnostics is incredibly promising. Advances in EV isolation and characterization techniques, coupled with the standardization of protocols and regulatory guidelines, will facilitate the clinical translation of EV-based products. Emerging technologies, including microfluidics-based isolation methods, single-vesicle analysis, and advanced imaging modalities, will enable deeper insights into EV biology and function, driving further innovation in the field. Moreover, collaborative efforts between researchers, clinicians, industry stakeholders, and regulatory agencies will be

essential for advancing EV research and realizing its full potential in clinical practice. Ultimately, EV-based therapies and diagnostics hold the promise of personalized and precision medicine, offering tailored treatments and diagnostic approaches that improve patient outcomes and quality of life.

References

1. Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. *Cell Mol Neurobiol*. 2016;36(3):301-312. doi:10.1007/s10571-016-0366-z

2. Yu J, Sane S, Kim JE, et al. Biogenesis and delivery of extracellular vesicles: harnessing the power of EVs for diagnostics and therapeutics. *Front Mol Biosci*. 2023;10. doi:10.3389/fmolb.2023.1330400

3. Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. *Cell Communication and Signaling*. 2021;19(1). doi:10.1186/s12964-021-00730-1

4. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. *Cells*. 2019;8(7). doi:10.3390/cells8070727

5. Turturici G, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: Advantages and disadvantages. *Am J Physiol Cell Physiol*. 2014;306(7). doi:10.1152/ajpcell.00228.2013

6. Papareddy P, Tapken I, Kroh K, et al. The role of extracellular vesicle fusion with target cells in triggering systemic inflammation. *Nat Commun*. 2024;15(1). doi:10.1038/s41467-024-45125-1

7. Zappulli V, Pagh Friis K, Fitzpatrick Z, Maguire CA, Breakefield XO. Extracellular vesicles and intercellular communication within the nervous system. *Journal of Clinical Investigation*. 2016;126(4):1198-1207. doi:10.1172/JCI81134

8. Paolicelli RC, Bergamini G, Rajendran L. Cell-to-cell Communication by Extracellular Vesicles: Focus on Microglia. *Neuroscience*. 2019;405:148-157. doi:10.1016/j.neuroscience.2018.04.003

9. Cano A, Ettcheto M, Bernuz M, et al. Extracellular vesicles, the emerging mirrors of brain physiopathology. *Int J Biol Sci*. 2023;19(3):721-743. doi:10.7150/ijbs.79063

10. Yu J, Sane S, Kim JE, et al. Biogenesis and delivery of extracellular vesicles: harnessing the power of EVs for diagnostics and therapeutics. *Front Mol Biosci*. 2023;10. doi:10.3389/fmolb.2023.1330400

11. Liao Y, Yi Q, He J, et al. Extracellular vesicles in tumorigenesis, metastasis, chemotherapy resistance and intercellular communication in osteosarcoma. *Bioengineered*. 2023;14(1):113-128. doi:10.1080/21655979.2022.2161711

12. Ma Y, Ma QW, Sun Y, Chen XF. The emerging role of extracellular vesicles in the testis. *Hum Reprod*. 2023;38(3):334-351. doi:10.1093/humrep/dead015

13. Tatischeff I. *Extracellular Vesicles as Intercellular Communication Messengers Involved in Human Skin Health and Disease*. Vol 2.; 2020. www.revintercell.com

14. Trappe A, Donnelly SC, McNally P, Coppinger JA. Role of extracellular vesicles in chronic lung disease. *Thorax*. 2021;76(10):1047-1056. doi:10.1136/thoraxjnl-2020-216370

15. Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. *Cell Communication and Signaling*. 2021;19(1). doi:10.1186/s12964-021-00730-1

16. Godakumara K, Dissanayake K, Hasan MM, Kodithuwakku SP, Fazeli A. Role of extracellular vesicles in intercellular communication during reproduction. *Reproduction in Domestic Animals*. 2022;57(S5):14-21. doi:10.1111/rda.14205

17. Bonner SE, Willms E. Intercellular communication through extracellular vesicles in cancer and evolutionary biology. *Prog Biophys Mol Biol*. 2021;165:80-87. doi:10.1016/j.pbiomolbio.2021.08.006

18. Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. *Endocrine*. 2013;44(1):11-19. doi:10.1007/s12020-012-9839-0

19. Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. *Cell Mol Neurobiol*. 2016;36(3):301-312. doi:10.1007/s10571-016-0366-z

20. Correa R, Caballero Z, De León LF, Spadafora C. Extracellular Vesicles Could Carry an Evolutionary Footprint in Interkingdom Communication. *Front Cell Infect Microbiol*. 2020;10. doi:10.3389/fcimb.2020.00076

21. Michans EB. *Development of an IoT Network for Elderly Healthcare*.; 2021.

22. Sagdic K, Eş I, Sitti M, Inci F. Smart materials: rational design in biosystems via artificial intelligence. *Trends Biotechnol*. 2022;40(8):987-1003. doi:10.1016/j.tibtech.2022.01.005

23. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. *Cells*. 2019;8(7). doi:10.3390/cells8070727

24. Giebel B. On the function and heterogeneity of extracellular vesicles. *Ann Transl Med*. 2017;5(6). doi:10.21037/atm.2017.02.14

25. Alsawaier RS. The effect of gamification on motivation and engagement. *International Journal of Information and Learning Technology*. 2018;35(1):56-79. doi:10.1108/IJILT-02-2017-0009

26. Papareddy P, Tapken I, Kroh K, et al. The role of extracellular vesicle fusion with target cells in triggering systemic inflammation. *Nat Commun*. 2024;15(1). doi:10.1038/s41467-024-45125-1

27. Yu J, Sane S, Kim JE, et al. Biogenesis and delivery of extracellular vesicles: harnessing the power of EVs for diagnostics and therapeutics. *Front Mol Biosci*. 2023;10. doi:10.3389/fmolb.2023.1330400

28. Liao Y, Yi Q, He J, et al. Extracellular vesicles in tumorigenesis, metastasis, chemotherapy resistance and intercellular communication in osteosarcoma. *Bioengineered*. 2023;14(1):113-128. doi:10.1080/21655979.2022.2161711

29. van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol Rev*. 2012;64(3):676-705. doi:10.1124/pr.112.005983

30. Iša P, Pérez-Delgado A, Quevedo IR, López S, Arias CF. Rotaviruses associate with distinct types of extracellular vesicles. *Viruses*. 2020;12(7). doi:10.3390/v12070763

31. Mebarek S, Buchet R, Pikula S, et al. Do Media Extracellular Vesicles and Extracellular Vesicles Bound to the Extracellular Matrix Represent Distinct Types of Vesicles? *Biomolecules*. 2024;14(1). doi:10.3390/biom14010042

32. Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling.

Cell Communication and Signaling. 2021;19(1). doi:10.1186/s12964-021-00730-1

33. Correa R, Caballero Z, De León LF, Spadafora C. Extracellular Vesicles Could Carry an Evolutionary Footprint in Interkingdom Communication. *Front Cell Infect Microbiol*. 2020;10. doi:10.3389/fcimb.2020.00076

34. Yoon YJ, Kim OY, Gho YS. Extracellular vesicles as emerging intercellular communicasomes. *BMB Rep*. 2014;47(10):531-539. doi:10.5483/BMBRep.2014.47.10.164

35. Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. *Endocrine*. 2013;44(1):11-19. doi:10.1007/s12020-012-9839-0

36. Giebel B. On the function and heterogeneity of extracellular vesicles. *Ann Transl Med*. 2017;5(6). doi:10.21037/atm.2017.02.14

37. Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. *Bioscience*. 2015;65(8):783-797. doi:10.1093/biosci/biv084

38. Margolis L, Sadovsky Y. The biology of extracellular vesicles: The known unknowns. *PLoS Biol*. 2019;17(7). doi:10.1371/journal.pbio.3000363

39. Yu S, Zhao Z, Xu X, Li M, Li P. Characterization of three different types of extracellular vesicles and their impact on bacterial growth. *Food Chem*. 2019;272:372-378. doi:10.1016/j.foodchem.2018.08.059

40. Meckes DG, Raab-Traub N. Microvesicles and Viral Infection. *J Virol*. 2011;85(24):12844-12854. doi:10.1128/jvi.05853-11

41. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. *Trends Cell Biol*. 2009;19(2):43-51. doi:10.1016/j.tcb.2008.11.003

42. Sedgwick AE, D'Souza-Schorey C. The biology of extracellular microvesicles. *Traffic*. 2018;19(5):319-327. doi:10.1111/tra.12558

43. Anand S, Samuel M, Mathivanan S. Exomeres: A New Member of Extracellular Vesicles Family. In: *Subcellular Biochemistry*. Vol 97. Springer Science and Business Media B.V.; 2021:89-97. doi:10.1007/978-3-030-67171-6_5

44. Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: Disease message and therapeutic target potentials. *Biosci Rep*. 2019;39(1). doi:10.1042/BSR20180992

45. Battistelli M, Falcieri E. Apoptotic bodies: Particular extracellular vesicles involved in intercellular communication. *Biology (Basel)*. 2020;9(1). doi:10.3390/biology9010021

46. Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. *Exp Cell Res*. 2000;260(2):248-256. doi:10.1006/excr.2000.5027

47. Jiang L, Paone S, Caruso S, et al. Determining the contents and cell origins of apoptotic bodies by flow cytometry. *Sci Rep*. 2017;7(1). doi:10.1038/s41598-017-14305-z

48. Osterlund MT, Hardtke CS, Wei N, et al. *"Eat Me" Signals of Apoptotic Bodies*. Vol 405.; 2000. www.nature.com/ncb

49. Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. *Blood*. 2004;104(9):2761-2766. doi:10.1182/blood-2003-10-3614

50. Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake.

Cell Mol Neurobiol. 2016;36(3):301-312. doi:10.1007/s10571-016-0366-z

51. Lai RC, Tan SS, Yeo RWY, et al. MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA. *J Extracell Vesicles*. 2016;5(1). doi:10.3402/jev.v5.29828

52. Vagner T, Chin A, Mariscal J, Bannykh S, Engman DM, Di Vizio D. Protein Composition Reflects Extracellular Vesicle Heterogeneity. *Proteomics*. 2019;19(8). doi:10.1002/pmic.201800167

53. Jiang L, Vader P, Schiffelers RM. Extracellular vesicles for nucleic acid delivery: Progress and prospects for safe RNA-based gene therapy. *Gene Ther*. 2017;24(3):157-166. doi:10.1038/gt.2017.8

54. Pathan M, Fonseka P, Chitti S V., et al. Vesiclepedia 2019: A compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. *Nucleic Acids Res*. 2019;47(D1):D516-D519. doi:10.1093/nar/gky1029

55. Wang BZ, Luo LJ, Vunjak-Novakovic G. RNA and Protein Delivery by Cell-Secreted and Bioengineered Extracellular Vesicles. *Adv Healthc Mater*. 2022;11(5). doi:10.1002/adhm.202101557

56. Russell AE, Sneider A, Witwer KW, et al. Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop. In: *Journal of Extracellular Vesicles*. Vol 8. Taylor and Francis Ltd.; 2019. doi:10.1080/20013078.2019.1684862

57. Pocsfalvi G, Stanly C, Vilasi A, et al. Mass spectrometry of extracellular vesicles. *Mass Spectrom Rev*. 2016;35(1):3-21. doi:10.1002/mas.21457

58. van der Koog L, Gandek TB, Nagelkerke A. Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. *Adv Healthc Mater*. 2022;11(5). doi:10.1002/adhm.202100639

59. Mir B, Goettsch C. Extracellular vesicles as delivery vehicles of specific cellular cargo. *Cells*. 2020;9(7):1-19. doi:10.3390/cells9071601

60. Oshchepkova A, Zenkova M, Vlassov V. Extracellular Vesicles for Therapeutic Nucleic Acid Delivery: Loading Strategies and Challenges. *Int J Mol Sci*. 2023;24(8). doi:10.3390/ijms24087287

61. Sivanantham A, Jin Y. Impact of Storage Conditions on EV Integrity/Surface Markers and Cargos. *Life*. 2022;12(5). doi:10.3390/life12050697

62. Stremersch S, De Smedt SC, Raemdonck K. Therapeutic and diagnostic applications of extracellular vesicles. *Journal of Controlled Release*. 2016;244:167-183. doi:10.1016/j.jconrel.2016.07.054

63. Wiklander OPB, Brennan M, Lötvall J, Breakefield XO, Andaloussi SEL. Advances in therapeutic applications of extracellular vesicles. *Sci Transl Med*. 2019;11(492). doi:10.1126/scitranslmed.aav8521

64. György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: Clinical promise and open questions. *Annu Rev Pharmacol Toxicol*. 2015;55:439-464. doi:10.1146/annurev-pharmtox-010814-124630

65. Lv LL, Wu WJ, Feng Y, Li ZL, Tang TT, Liu BC. Therapeutic application of extracellular vesicles in kidney disease: promises and challenges. *J Cell Mol Med*. 2018;22(2):728-737. doi:10.1111/jcmm.13407

66. Oshchepkova A, Zenkova M, Vlassov V. Extracellular Vesicles for Therapeutic Nucleic Acid Delivery: Loading Strategies and Challenges. *Int J Mol Sci*. 2023;24(8). doi:10.3390/ijms24087287

67. Huber SC, Montalvão SADL, Sachetto Z, De Paula EV, Annichino-Bizzacchi JM. Autologous Platelet Rich Plasma (PRP) Provoke Immunomodulatory Response By an Increase of Regulatory T Cells (CD4+ CD25+ FOXP3+) with a Decrease of Activated NK Cells (CD16+ CD56+ CD69+) in a Longitudinal Study of Patients with BehçEt's Disease. *Blood*. 2016;128(22):3849-3849. doi:10.1182/blood.v128.22.3849.3849

68. Mukherjee S, Bhunia AS, Bhunia NS, Ray M, Ray S. Immunomodulatory effects of temperature and pH of water in an Indian freshwater sponge. *J Therm Biol*. 2016;59:1-12. doi:10.1016/j.jtherbio.2016.04.005

69. Haq A, Lobo PI, Al-Tufail M, Rama NR, Al-Sedairy T. *Immunomodulatory E€ ect of Nigella Sativa Proteins Fractionated by Ion Exchange Chromatography*. Vol 21.; 1999.

70. Dang L, Liu J, Li F, et al. Targeted delivery systems for molecular therapy in skeletal disorders. *Int J Mol Sci*. 2016;17(3). doi:10.3390/ijms17030428

71. Peer D, KarP JM, Hong S, faroKHzaD oMiD C, Margalit riMona, langer robert. *Nanocarriers as an Emerging Platform for Cancer Therapy*.; 2007. www.nature.com/naturenanotechnology

72. Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F, Capellá G. *Recent Advances in Cancer Therapy: An Overview*. Vol 16.; 2010.

73. Xie F, Zhou X, Fang M, et al. Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. *Advanced Science*. 2019;6(24). doi:10.1002/advs.201901779

74. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. *Clin Chem*. 2013;59(1):85-93. doi:10.1373/clinchem.2012.185363

75. Joyce JA. Therapeutic targeting of the tumor microenvironment. *Cancer Cell*. 2005;7(6):513-520. doi:10.1016/j.ccr.2005.05.024

76. Whittingham TA. Medical diagnostic applications and sources. *Prog Biophys Mol Biol*. 2007;93(1-3):84-110. doi:10.1016/j.pbiomolbio.2006.07.004

77. Ungerer JPJ, Oosthuizen HM, Blssbort SH, Vermaak WJH. *Serum AdenosineDeaminase:Isoenzymesand DiagnosticApplication*. Vol 38.; 1992.

78. Daher RK, Stewart G, Boissinot M, Bergeron MG. Recombinase polymerase amplification for diagnostic applications. *Clin Chem*. 2016;62(7):947-958. doi:10.1373/clinchem.2015.245829

79. Landsberg J. Modelling forest ecosystems: State of the art, challenges, and future directions. In: *Canadian Journal of Forest Research*. Vol 33. ; 2003:385-397. doi:10.1139/x02-129

80. Hu Y, Gao S, Lunga D, Li W, Newsam S, Bhaduri B. GeoAI at ACM SIGSPATIAL. *SIGSPATIAL Special*. 2019;11(2):5-15. doi:10.1145/3377000.3377002

81. Berking M, Wupperman P. Emotion regulation and mental health: Recent findings, current challenges, and future directions. *Curr Opin Psychiatry*. 2012;25(2):128-134. doi:10.1097/YCO.0b013e3283503669

82. Jaeger PT, Thompson KM. E-government around the world: Lessons, challenges, and future directions. *Gov Inf Q*. 2003;20(4):389-394. doi:10.1016/j.giq.2003.08.001